HighTower Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
VCM
VPM
HighTower Advisors's VRTX Position: Q1 2026 in Review
HighTower Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 38% in Q1 2026, buying an estimated $8.45M and bringing the position to 65,684 shares worth $29.3M. The position accounts for 0.03% of the portfolio, ranked #498.
HighTower Advisors first reported a position in VRTX in Q2 2013 and has held it in 51 quarters since. The position peaked at $33.4M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- HighTower Advisors held 65,684 shares of Vertex Pharmaceuticals worth $29.3M as of Q1 2026.
- HighTower Advisors bought 18,125 Vertex Pharmaceuticals shares in Q1 2026, an estimated $8.45M.
- Vertex Pharmaceuticals made up 0.03% of HighTower Advisors's portfolio in Q1 2026, its #498 holding.
- HighTower Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- HighTower Advisors's Vertex Pharmaceuticals position peaked at $33.4M in Q4 2023.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.